Phaseline

Targets › ALK

ALK (ALK tyrosine kinase receptor): drug programs, companies and trials

26 programs from 23 companies in 92 trials: 46 Phase 2, 27 Phase 1, 13 Phase 3, 6 Phase 4; Oncology; next expected readout Nov 2026.

Neuronal receptor tyrosine kinase that is essentially and transiently expressed in specific regions of the central and peripheral nervous systems and plays an important role in the genesis and differentiation of the nervous system. Also acts as a key thinness protein involved in the resistance to weight gain: in hypothalamic neurons, controls energy expenditure acting as a negative regulator of white adipose tissue…. (UniProt, Q9UM73)

Open in Phaseline: the race on ALK, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
NovartisCeritinib (LDK378)
ALK tyrosine kinase receptor inhibitor; EML4-ALK inhibitor; NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) inhibitor
ALK, EML4, NPM1Phase 4ALK Positive Malignancies; ALK-positive NSCLC; Neuroblastoma; ALK Positive …Apr 2027
Pfizercrizotinib
Hepatocyte growth factor receptor inhibitor; ALK tyrosine kinase receptor inhibitor; EML4-ALK inhibitor
MET, ALK, EML4, NPM1, ROS1Phase 4NSCLCMar 2028
PfizerLorlatinib (PF-06463922)
ALK tyrosine kinase receptor inhibitor; EML4-ALK inhibitor
ALK, EML4Phase 4Non-Small-Cell Lung Cancer; Carcinoma, Non-Small-Cell Lung; Ganglioneuroblastoma; Non Small Cell Lung Cancer …Dec 2028
PfizerLorlatanib
ALK inhibitor
ALKPhase 3Advanced MalignanciesDec 2026
IDEAYA BiosciencesCrizotinib
Hepatocyte growth factor receptor inhibitor; ALK tyrosine kinase receptor inhibitor; EML4-ALK inhibitor
MET, ALK, EML4, NPM1, ROS1Phase 3Uveal Melanoma; Metastatic Uveal Melanoma; ALK Gene Rearrangement; Advanced Lymphoma …Jan 2027
RocheAlectinib
ALK tyrosine kinase receptor inhibitor; Tyrosine-protein kinase receptor RET inhibitor; EML4-ALK inhibitor
ALK, RET, EML4Phase 3Non-Small Cell Lung Cancer; Carcinoma, Non-Small-Cell Lung; Solid Tumors; ALK Fusion-positive Solid or CNS Tumors …Jan 2027
RocheEntrectinib (RXDX-101)
Neurotrophic tyrosine kinase receptor inhibitor; Proto-oncogene tyrosine-protein kinase ROS inhibitor; ALK tyrosine kinase receptor inhibitor
NTRK1, NTRK2, NTRK3, ROS1, ALKPhase 3Non-Small Cell Lung Cancer; Carcinoma, Non-Small-Cell Lung; Breast Cancer; Solid Tumors …Jan 2027
NuvalentNeladalkib (NVL-655)
ALK inhibitor
ALKPhase 3Non-small Cell Lung Cancer; Locally Advanced Solid TumorDec 2027
Shanghai Fosun Pharmaceutical Industrial DevelopmentForitinib Succinate (SAF-189s)
ALK inhibitor
ALKPhase 3Non-Small Cell Lung CancerDec 2027
Shenzhen TargetRxTGRX-326
ALK inhibitor
ALKPhase 3Non Small Cell Lung Cancer; Non-small Cell Lung CancerNov 2028
Xcovery HoldingsEnsartinib (X-396)
ALK tyrosine kinase receptor inhibitor
ALKPhase 3Non-small Cell Lung Cancer–
Fundación GECPBrigatinib
ALK tyrosine kinase receptor inhibitor; Epidermal growth factor receptor erbB1 inhibitor
ALK, EGFRPhase 2Lung CancerNov 2026
Pingping SongWX-0593
ALK and ROS1 tyrosine kinase inhibitor
ALK, ROS1Phase 2Non-Small Cell Lung Cancer(NSCLC)Mar 2027
CStone PharmaceuticalsLorlatinib
ALK tyrosine kinase receptor inhibitor; EML4-ALK inhibitor
ALK, EML4Phase 2Advanced or Metastatic ROS1-Positive Non-Small Cell Lung CancerMay 2027
University Health Network, TorontoBrigatinib
ALK tyrosine kinase receptor inhibitor; Epidermal growth factor receptor erbB1 inhibitor
ALK, EGFRPhase 2Pancreatic Ductal CarcinomaFeb 2028
Intergroupe Francophone de Cancerologie ThoraciqueBrigatinib
ALK tyrosine kinase receptor inhibitor; Epidermal growth factor receptor erbB1 inhibitor
ALK, EGFRPhase 2Non Small Cell Lung CancerOct 2028
Scott R. Plotkin, MD, PhDBrigatinib
ALK tyrosine kinase receptor inhibitor; Epidermal growth factor receptor erbB1 inhibitor
ALK, EGFRPhase 2Neurofibromatosis Type 2Dec 2029
Groupe Francais De Pneumo-CancerologieBrigatinib
ALK tyrosine kinase receptor inhibitor; Epidermal growth factor receptor erbB1 inhibitor
ALK, EGFRPhase 2NSCLCOct 2030
City of Hope Medical CenterBrigatinib
ALK tyrosine kinase receptor inhibitor; Epidermal growth factor receptor erbB1 inhibitor
ALK, EGFRPhase 1Locally Advanced Lung Non-Small Cell CarcinomaMar 2027
Ascentage Pharma GroupAPG-2449
Multi-targeted tyrosine kinase inhibitor; FAK, ALK, and ROS1 inhibitor
FAK, ALK, ROS1Phase 1Platinum-resistant Recurrent Ovarian Cancer; Advanced Solid CancerMay 2027
Roberto ChiarleAutologous hALK.CAR T cells
Chimeric antigen receptor T cells targeting Anaplastic Lymphoma Kinase (ALK)
ALKPhase 1Relapsed NeuroblastomaDec 2027
M.D. Anderson Cancer CenterBrigatinib
ALK tyrosine kinase receptor inhibitor; Epidermal growth factor receptor erbB1 inhibitor
ALK, EGFRPhase 1Advanced Lung Carcinoma; Brain MetastasisJun 2028
Shouyao Holdings (Beijing) Co. LTDSY-12321
Fourth-generation ALK tyrosine kinase inhibitor
ALKPhase 1ALK Positive Advanced MalignanciesAug 2028
Betta PharmaceuticalsEnsartinib
ALK tyrosine kinase receptor inhibitor
ALKPhase 1Solid Advanced Tumor; Nonsmall Cell Lung Cancer; Non-Small Cell Lung Cancer; Advanced Malignant Solid Neoplasm …Feb 2029
TRIANA BiomedicinesTRI-611
ALK molecular glue degrader
ALKPhase 1ALK-positive NSCLCMay 2029
Princess Maxima Center for Pediatric OncologyBrigatinib
ALK tyrosine kinase receptor inhibitor; Epidermal growth factor receptor erbB1 inhibitor
ALK, EGFRPhase 1Anaplastic Large Cell Lymphoma, ALK-PositiveDec 2033

Conditions

Non-small Cell Lung Cancer (8) Non-Small Cell Lung Cancer (6) Non Small Cell Lung Cancer (5) Advanced Lymphoma (4) Carcinoma, Non-Small-Cell Lung (4) Haematological Malignancy (4) Advanced Malignant Solid Neoplasm (3) Solid Tumors (3) Metastatic Colorectal Cancer (2) Lung Cancer (2) Brain Metastasis (2) ALK-positive NSCLC (2)

Modalities

small molecule (19), mixed (4), other (1), protein or peptide (1)

Companies

Pfizer (3) Roche (2) IDEAYA Biosciences (1) Pingping Song (1) Roberto Chiarle (1) Shouyao Holdings (Beijing) Co. LTD (1) CStone Pharmaceuticals (1) Scott R. Plotkin, MD, PhD (1) Ascentage Pharma Group (1) Novartis (1) Shenzhen TargetRx (1) University Health Network, Toronto (1) Nuvalent (1) Fundación GECP (1) Groupe Francais De Pneumo-Cancerologie (1) City of Hope Medical Center (1) Shanghai Fosun Pharmaceutical Industrial Development (1) M.D. Anderson Cancer Center (1) TRIANA Biomedicines (1) Betta Pharmaceuticals (1)

Related targets

EGFR (8) EML4 (6) ROS1 (5) NPM1 (3) MET (2) RET (1) NTRK1 (1) NTRK2 (1) NTRK3 (1) FAK (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.